ADAM metallopeptidase domain 33 (ADAM33): A promising target for asthma

Priya Tripathi, Shally Awasthi, Peisong Gao

Research output: Contribution to journalArticle

Abstract

Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy.

Original languageEnglish (US)
Article number572025
JournalMediators of Inflammation
Volume2014
DOIs
StatePublished - 2014

Fingerprint

Metalloproteases
Asthma
Epigenomics
Airway Remodeling
Disintegrins
Environmental Exposure
DNA Methylation
Genetic Predisposition to Disease
Population
Smooth Muscle Myocytes
Meta-Analysis
Cell Differentiation
Epithelium
Fibroblasts
Cell Proliferation
Genes

ASJC Scopus subject areas

  • Immunology
  • Cell Biology
  • Medicine(all)

Cite this

ADAM metallopeptidase domain 33 (ADAM33) : A promising target for asthma. / Tripathi, Priya; Awasthi, Shally; Gao, Peisong.

In: Mediators of Inflammation, Vol. 2014, 572025, 2014.

Research output: Contribution to journalArticle

@article{196e9caa29024f209fbe3cce17c59df0,
title = "ADAM metallopeptidase domain 33 (ADAM33): A promising target for asthma",
abstract = "Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy.",
author = "Priya Tripathi and Shally Awasthi and Peisong Gao",
year = "2014",
doi = "10.1155/2014/572025",
language = "English (US)",
volume = "2014",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - ADAM metallopeptidase domain 33 (ADAM33)

T2 - A promising target for asthma

AU - Tripathi, Priya

AU - Awasthi, Shally

AU - Gao, Peisong

PY - 2014

Y1 - 2014

N2 - Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy.

AB - Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy.

UR - http://www.scopus.com/inward/record.url?scp=84899950016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899950016&partnerID=8YFLogxK

U2 - 10.1155/2014/572025

DO - 10.1155/2014/572025

M3 - Article

C2 - 24817794

AN - SCOPUS:84899950016

VL - 2014

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 572025

ER -